Skip to main content

Table 1 Demographic, clinical, immunological and functional characteristics of scleroderma patients

From: Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis

Characteristic SScFib+ SScFib-
Number 9 6
Age, years (mean ± SD) 55.6 ± 10.3 50.5 ± 9.6
Cutaneous involvement   
   Lc SSc (percentage) 1 (11.1) 4 (66.7)
   Dc SSc (percentage) 8 (89.9) 2 (33.3)
   Skin score (mean ± SD) 17.0 ± 8.0 10.0 ± 6.0
Autoantibodies   
   ANA positive (percentage) 9 (100) 6 (100)
   Anti-Scl70 positive (percentage) 7 (77.7) 2 (33)
Lung function test   
   FVC, percentage predicted (mean ± SD) 80.9 ± 11.7a 118.7 ± 11.6
   TLCO, percentage predicted (mean ± SD) 60.01 ± 12.6a 72.03 ± 13.8
   Kazerooni score 10.0 ± 5 0
  1. Skin score and Kazerooni score for fibrosis were determined as described previously [9,11]. SScFib+, systemic sclerosis patients with functional lung fibrosis and signs of lung fibrosis on high-resolution computed tomography; SScFib-, SSc patients with no signs and symptoms of lung involvement; Lc SSc, limited cutaneous SSc; Dc SSc, diffuse cutaneous SSc; ANA, antinuclear antibodies; anti-Scl70, anti-topoisomerase I antibodies; FVC, forced vital capacity; TLCO, carbon monoxide transfer. aDecrease more than 20% with regard to the expected TLCO or FVC values.